Articles
- · 9 min read
Ten pharma conferences to watch this autumn
Five clinical congresses where pharma are launching and five commercial events where pharma are speaking — with the brands, companies, roles and costs behind each one.
Read article → - · 3 min read
Try Doing This: Drug Updates Mapped to Stakeholders
How Athena BDA maps drug updates — approvals, indications, pipeline news and acquisitions — directly to the stakeholders working on the brand.
Read article → - · 4 min read
August’s 6 Most Important Drug Updates
We tracked 31 pharma news catalysts in August across approvals, new indication approvals, positive Phase 3 results and NDA updates. Here are the six that matter most — Lipfendra, AMT-130, cemdisiran, ivonescimab, mezigdomide and Gazyva.
Read article → - · 4 min read
Introducing Vertical Sales Intelligence
Today we’re announcing an expanded vision for Athena BDA which is to create a new category called Vertical Sales Intelligence.
Read article → - · 6 min read
Athena Intelligence Hub — Recent Updates
A round-up of the latest Intelligence Hub releases: the Athena MCP Lite connector for Claude and ChatGPT, expanded Key Drug Database views, richer conference intelligence, a full Scoring & Connection Center, a new Learning Center, clearer co-promote handling and Contact Portal quick filters.
Read article → - · 5 min read
Pipeline & Launch Brand Alerts — July 2026
We tracked 26 pharma news catalysts in July across approvals, new indication approvals, positive Phase 3 readouts and M&A. Here are the updates that matter most — led by tulisokibart, zasocitinib and Utebzi.
Read article → - · 5 min read
Pipeline & Launch Brand Alerts — May 2026
We tracked 29 pharma news catalysts in May across approvals, new indication approvals, positive Phase 3 readouts and M&A. Here are the updates that matter most — led by Azetukalner, daraxonrasib and Novo Nordisk’s rare blood franchise.
Read article → - · 7 min read
Top 10 Biotech Pipelines to Watch in 2026
Small to mid-sized biotechs ranked by the strength of their recently approved and late-stage assets — looking at pipeline depth, estimated peak sales and recent GTM hiring activity.
Read article → - · 7 min read
How to build an AI messaging assistant using Athena BDA data
AI messaging only works when it has the right structure around it. Here is the four-layer framework we use to turn pharma data into personalised, accurate outreach.
Read article → - · 6 min read
10 Pipeline Drugs to Watch in 2026
Tracking launch brands offers one of the biggest opportunities to smash your targets. These 10 pipeline drugs stand out on commercial potential, clinical or regulatory momentum, and stakeholder activity already forming around the brand.
Read article → - · 5 min read
Pipeline & Launch Brand Alerts — March 2026
We tracked 27 pharma news catalysts in March across approvals, new indication approvals, positive Phase 3 readouts and M&A. Here are the updates that matter most — led by infigratinib, iberdomide and QTORIN rapamycin gel.
Read article → - · 4 min read
February 2026 Pipeline News Digest — Hot Tip Alerts
Our February pipeline briefing covers the highest-priority Phase 3 results, recent approvals and acquisition activity shaping pharma — led by GSK’s bepirovirsen, Alumis’ envudeucitinib and Abivax’s obefazimod.
Read article → - · 5 min read
Pipeline & Launch Brand Alerts — November 2025 (Insights Hub Launch)
We tracked 20+ major updates in November, including multiple FDA approvals, NDA/BLA submissions and positive Phase 3 readouts — many tied to assets projected to generate $1B+ in peak annual sales. Plus: the launch of the Athena BDA Pharma Insights Hub.
Read article → - · 5 min read
Pipeline & Launch Brand Alerts — September 2025
In September we tracked 28 significant updates — 4 FDA approvals, 2 new indication approvals and multiple positive Phase 3 readouts, most tied to brands projected to generate $1B+ annually. Top Hot Tips: iberdomide, pegozafermin and Palsonify.
Read article → - · 5 min read
Pipeline & Launch Brand Alerts — August 2025
In August we tracked 21 significant updates: 9 FDA approvals, 2 new indication approvals and 10 pipeline news catalysts. Top Hot Tips: gedatolisib, ianalumab and Wegovy in MASH.
Read article → - · 5 min read
Pipeline & Launch Brand Alerts — July 2025
In July we tracked 22 significant updates: 7 FDA approvals and 15 pipeline news catalysts. Top Hot Tips: baxdrostat, oveporexton and zidesamtinib.
Read article → - · 5 min read
Pipeline & Launch Brand Alerts — June 2025
In June we tracked 24 significant updates: 8 FDA approvals, 2 new indication approvals and 14 pipeline news catalysts. Top Hot Tips: orforglipron and efsitora alfa, enlicitide decanoate and ziftomenib.
Read article →